NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.
You may also be interested in...
The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.
Roche Holding AG hopes the UK's National Institute for Health and Care Excellence will continue seeking possible ways to provide the Swiss drug maker's breast cancer therapy Kadcyla (ado-trastuzumab emtansine) on the publicly-funded National Health Service despite rejecting it in final guidance on cost grounds.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.